Immucell (ICCC) Construction in Progress (2011 - 2024)

Immucell's (ICCC) quarterly Construction in Progress came in at $2.3 million in Q4 2024, up 578.1% quarter-over-quarter from $341683.0 in Q4 2022.

Analysis

Immucell (ICCC) Construction in Progress (2011 - 2024) Analysis & Trends

Immucell (ICCC) has reported Construction in Progress for 8 consecutive years, with $2.3 million the latest figure, recorded in Q4 2024.

For the quarter ending Q4 2024, Construction in Progress changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2024 stood at $2.3 million (changed N/A YoY), and the FY2024 full-year result was $2.3 million, changed N/A from the prior year.
Construction in Progress advanced to $2.3 million in Q4 2024 per ICCC's latest filing, from $341683.0 in the prior quarter.
Across five years, Construction in Progress topped out at $2.3 million in Q4 2024 and bottomed at $341683.0 in Q4 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Idexx Laboratories	40.31 Bn	40.12 Bn	779.09 Mn	-
2	Zoetis	30.56 Bn	28.88 Bn	1.05 Bn	-
3	Elanco Animal Health	11.54 Bn	11.01 Bn	798.00 Mn	-
4	Phibro Animal Health	1.49 Bn	1.40 Bn	134.40 Mn	-
5	Immucell	89.38 Mn	80.52 Mn	2.44 Mn	-
6	Zhengye Biotechnology Holding	76.69 Mn	69.60 Mn	-	86,005.49
7	Global Innovative Platforms	24.88 Mn	24.63 Mn	-	-

Historic Data

Download Data